Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/1998

01-10-1998 | ORIGINAL ARTICLE

Lack of correlation of MRP and γ-glutamylcysteine synthetase overexpression with doxorubicin resistance due to increased apoptosis in SV40 large T-antigen-transformed human mesothelial cells

Authors: Besim Ogretmen, Hamid Bahadori, Mary McCauley, Alice Boylan, Mark Green, Ahmad R. Safa

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/1998

Login to get access
Metadata
Title
Lack of correlation of MRP and γ-glutamylcysteine synthetase overexpression with doxorubicin resistance due to increased apoptosis in SV40 large T-antigen-transformed human mesothelial cells
Authors
Besim Ogretmen
Hamid Bahadori
Mary McCauley
Alice Boylan
Mark Green
Ahmad R. Safa
Publication date
01-10-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050843

Other articles of this Issue 6/1998

Cancer Chemotherapy and Pharmacology 6/1998 Go to the issue

ORIGINAL ARTICLE

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors

SHORT COMMUNICATIONS

Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration

ORIGINAL ARTICLE

Antihelicase action of CI-958, a new drug for prostate cancer

ORIGINAL ARTICLE

Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil

ORIGINAL ARTICLE

Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer

SHORT COMMUNICATION

Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits